Nothing said here yet.
to join the conversation.
The updated analyst fair value estimate for Integra LifeSciences Holdings has shifted from US$18.38 to US$16.44, which points to a roughly 11% cut in where models now anchor the stock’s longer term potential.
Medical device company Integra LifeSciences (NASDAQ:IART) met Wall Street’s revenue expectations in Q3 2026, with sales up 2.3% year on year to $411.2 million.
Integra LifeSciences walked into this Q3 2026 report with the stock already under pressure, and the latest numbers triggered another sharp swing.
Shares of medical device company Integra LifeSciences (NASDAQ:IART) fell 7.3% in the afternoon session after the company reported third-quarter financial results featuring operational disruptions from plant flooding and projected a revenue contraction for the…
Operating cash flow hit a record even as the company navigates supply disruptions, a sign of underlying business resilience.
Cincinnati flooding hit revenue, but neurosurgery growth and refinancing support recovery.
Moby summary of Integra LifeSciences Holdings Corporation's Q3 2026 earnings call
Integra LifeSciences (NASDAQ:IART) reported third-quarter revenue at the low end of its guidance range as a flooding-related disruption at its Cincinnati facility and slower-than-expected Tissue Reconstruction performance weighed on results.
Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Medical device company Integra LifeSciences (NASDAQ:IART) met Wall Street’s revenue expectations in Q3 2026, with sales up 2.3% year on year to $411.2 million.